Summit Therapeutics (NASDAQ:SMMT – Get Free Report) had its price objective dropped by stock analysts at Barclays from $20.00 to $18.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price objective indicates a potential upside of 46.53% from the company’s previous close.
Several other brokerages have also recently weighed in on SMMT. HC Wainwright reissued a “buy” rating on shares of Summit Therapeutics in a report on Thursday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Summit Therapeutics in a research report on Thursday, October 15th. Summit Redstone set a $25.00 target price on shares of Summit Therapeutics in a research note on Wednesday, September 9th. Stifel Nicolaus lowered their price target on shares of Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, July 24th. Finally, Morgan Stanley cut shares of Summit Therapeutics to an “outperform” rating in a research report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.45.
Check Out Our Latest Stock Analysis on Summit Therapeutics
Summit Therapeutics Price Performance
Shares of SMMT stock traded down $1.87 on Monday, reaching $12.28. 9,824,309 shares of the stock were exchanged, compared to its average volume of 4,668,601. Summit Therapeutics has a one year low of $11.94 and a one year high of $29.23. The stock has a market cap of $9.82 billion, a PE ratio of -11.57 and a beta of -1.49. The stock has a 50 day moving average price of $16.41 and a 200 day moving average price of $16.14.
Hedge Funds Weigh In On Summit Therapeutics
Several institutional investors have recently modified their holdings of SMMT. IFP Advisors Inc raised its position in shares of Summit Therapeutics by 792.3% in the 3rd quarter. IFP Advisors Inc now owns 1,508 shares of the company’s stock valued at $26,000 after acquiring an additional 1,339 shares during the period. Toth Financial Advisory Corp acquired a new position in Summit Therapeutics during the third quarter valued at approximately $30,000. CX Institutional grew its holdings in Summit Therapeutics by 244.8% during the third quarter. CX Institutional now owns 2,038 shares of the company’s stock valued at $34,000 after purchasing an additional 1,447 shares during the period. Global Retirement Partners LLC grew its holdings in Summit Therapeutics by 200.0% during the third quarter. Global Retirement Partners LLC now owns 2,058 shares of the company’s stock valued at $35,000 after purchasing an additional 1,372 shares during the period. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Summit Therapeutics in the third quarter valued at approximately $34,000. 4.61% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Summit Therapeutics
These are some of the SMMT headlines that stood out recently:
- Neutral Sentiment: The company’s update confirms the FDA issued a CRL for ivonescimab with platinum-containing chemotherapy in previously treated, locally advanced or metastatic non-small cell lung cancer. Investors will be watching for details on the FDA’s concerns and Summit’s next steps. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- Negative Sentiment: The FDA setback to Summit’s lead cancer-drug application is the main catalyst weighing on SMMT. Reports said shares fell sharply, with one describing them at a 52-week low; the rejection delays the prospect of U.S. approval and adds risk to expectations for ivonescimab. Summit shares drop after US FDA declines to approve lung cancer drug Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
About Summit Therapeutics
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Featured Stories
- Five stocks we like better than Summit Therapeutics
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
